PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 12749886-0 2003 Binding mode of 6ECDCA, a potent bile acid agonist of the farnesoid X receptor (FXR). obeticholic acid 16-22 xenotropic and polytropic retrovirus receptor 1 Homo sapiens 68-78 32118303-1 2020 The farnesoid X receptor (FXR)-fibroblast growth factor 19 (FGF19) axis has provided promising therapeutic targets for nonalcoholic steatohepatitis (NASH), with obeticholic acid (OCA), the first-in-class FXR agonist, showing fibrosis improvement in two human trials. obeticholic acid 161-177 xenotropic and polytropic retrovirus receptor 1 Homo sapiens 14-24 30026040-1 2018 Activation of the nuclear farnesoid X receptor (FXR) which acts as cellular bile acid sensor has been validated as therapeutic strategy to counter liver disorders such as non-alcoholic steatohepatitis by the clinical efficacy of obeticholic acid. obeticholic acid 229-245 xenotropic and polytropic retrovirus receptor 1 Homo sapiens 36-46 31634532-1 2020 BACKGROUND: Farnesoid X receptor (FXR) agonist, obeticholic acid (OCA), increases total and low-density lipoprotein cholesterol (LDL-C) in patients with nonalcoholic steatohepatitis (NASH). obeticholic acid 48-64 xenotropic and polytropic retrovirus receptor 1 Homo sapiens 22-32 31634532-1 2020 BACKGROUND: Farnesoid X receptor (FXR) agonist, obeticholic acid (OCA), increases total and low-density lipoprotein cholesterol (LDL-C) in patients with nonalcoholic steatohepatitis (NASH). obeticholic acid 66-69 xenotropic and polytropic retrovirus receptor 1 Homo sapiens 22-32 31634532-12 2020 Recently, obeticholic acid (OCA), a farnesoid X receptor agonist, improved liver disease but led to an increase in cholesterol, however, the impact of OCA on cholesterol is not well understood. obeticholic acid 10-26 xenotropic and polytropic retrovirus receptor 1 Homo sapiens 46-56 31634532-12 2020 Recently, obeticholic acid (OCA), a farnesoid X receptor agonist, improved liver disease but led to an increase in cholesterol, however, the impact of OCA on cholesterol is not well understood. obeticholic acid 28-31 xenotropic and polytropic retrovirus receptor 1 Homo sapiens 46-56 31441502-4 2019 Potential second line treatments are also available when UDCA alone is not effective enough: the farnesoid X receptor (FXR) agonist obeticholic acid, conditionally approved by North American (FDA) and European (EMA) authorities as second line treatment in PBC, or the nonspecific peroxisomal proliferator-associated receptor (PPAR) agonist bezafibrate. obeticholic acid 132-148 xenotropic and polytropic retrovirus receptor 1 Homo sapiens 107-117 31254596-1 2019 BACKGROUND & AIMS: The nuclear farnesoid X receptor (FXR) agonist obeticholic acid (OCA) has been developed for the treatment of liver diseases. obeticholic acid 70-86 xenotropic and polytropic retrovirus receptor 1 Homo sapiens 45-55 31254596-1 2019 BACKGROUND & AIMS: The nuclear farnesoid X receptor (FXR) agonist obeticholic acid (OCA) has been developed for the treatment of liver diseases. obeticholic acid 88-91 xenotropic and polytropic retrovirus receptor 1 Homo sapiens 45-55 30254132-7 2018 Obeticholic acid dose dependently inhibited lipid accumulation and modulated gene expression downstream of the farnesoid X receptor. obeticholic acid 0-16 xenotropic and polytropic retrovirus receptor 1 Homo sapiens 121-131 28805978-0 2017 Obeticholic acid, a selective farnesoid X receptor agonist, regulates bile acid homeostasis in sandwich-cultured human hepatocytes. obeticholic acid 0-16 xenotropic and polytropic retrovirus receptor 1 Homo sapiens 40-50 29487110-0 2018 Farnesoid X Receptor Agonists Obeticholic Acid and Chenodeoxycholic Acid Increase Bile Acid Efflux in Sandwich-Cultured Human Hepatocytes: Functional Evidence and Mechanisms. obeticholic acid 30-46 xenotropic and polytropic retrovirus receptor 1 Homo sapiens 10-20 28746779-1 2018 BACKGROUND & AIMS: Treatment with the farnesoid X receptor (FXR) agonist obeticholic acid is ineffective in some patients with non-alcoholic steatohepatitis (NASH) but the explanation is uncertain. obeticholic acid 77-93 xenotropic and polytropic retrovirus receptor 1 Homo sapiens 52-62 27939613-2 2017 Obeticholic acid (OCA), a farnesoid X receptor (FXR) agonist, shows promise in NASH trials. obeticholic acid 0-16 xenotropic and polytropic retrovirus receptor 1 Homo sapiens 36-46 27939613-2 2017 Obeticholic acid (OCA), a farnesoid X receptor (FXR) agonist, shows promise in NASH trials. obeticholic acid 18-21 xenotropic and polytropic retrovirus receptor 1 Homo sapiens 36-46 25329562-0 2015 The response of patients with bile acid diarrhoea to the farnesoid X receptor agonist obeticholic acid. obeticholic acid 86-102 xenotropic and polytropic retrovirus receptor 1 Homo sapiens 67-77 27468093-14 2016 Six-ethyl chenodeoxycholic acid (6-ECDCA), a potent farnesoid X receptor (FXR) agonist, has shown anti-cholestatic activity in rodent models of cholestasis. obeticholic acid 33-40 xenotropic and polytropic retrovirus receptor 1 Homo sapiens 62-72 27743502-1 2016 Obeticholic acid (OCA), a semisynthetic bile acid, is a selective and potent farnesoid X receptor (FXR) agonist in development for the treatment of chronic nonviral liver diseases. obeticholic acid 0-16 xenotropic and polytropic retrovirus receptor 1 Homo sapiens 87-97 27743502-1 2016 Obeticholic acid (OCA), a semisynthetic bile acid, is a selective and potent farnesoid X receptor (FXR) agonist in development for the treatment of chronic nonviral liver diseases. obeticholic acid 18-21 xenotropic and polytropic retrovirus receptor 1 Homo sapiens 87-97 26642350-10 2015 The effect of new agents such obeticholic acid are promising, since the addition of this farnesoide-X-receptor agonist bile acid in patients with stable UDCA dosage and increased alkaline phosphatase levels results in an improvement of cholestasis as compared to placebo, with a parallel decrease of aminotransferases and immunoglobulin M, as well as one surrogate marker of bile acid synthesis. obeticholic acid 30-46 xenotropic and polytropic retrovirus receptor 1 Homo sapiens 100-110